Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. - Koishikawa T; Tomoda Y; Tsuchitani T; Taskar K; Yoshida K; Mao J; Takashima T; Lai Y; Sugiyama Y; Kusuhara H (Drug metabolism and disposition: the biological fate of chemicals, 2025)